文献速递妇科生殖医学

经阴道超声评估接受睾酮治疗的跨男性人群与顺性别女性的子宫内膜厚度比较

Endometrial thickness assessed by transvaginal ultrasound in transmasculine people taking testosterone compared with cisgender women.
PubMed 文献 · Reprod Biomed Online · 2022-06-22

单中心横断面队列研究在阿姆斯特丹性别焦虑专业中心开展,纳入2013至2015年拟行性别肯定手术且接受睾酮治疗至少1年的跨男性人群51例,与顺性别女性对照77例,经阴道超声测量子宫内膜厚度。跨男性人群中位厚度3.9 mm(IQR 2.8-5.1),顺性别女性为4.9 mm(IQR 4.0-6.3),校正当前促性腺激素释放激素激动剂使用这一混杂因素后差异有统计学意义(P < 0.001)。作者认为结果提示外源性睾酮不引起子宫内膜增殖。

要点

  • 跨男性人群接受睾酮治疗中位30.2个月(SD 8.8),子宫内膜中位厚度3.9 mm(IQR 2.8-5.1)。
  • 顺性别女性对照子宫内膜中位厚度4.9 mm(IQR 4.0-6.3),校正混杂因素后差异有统计学意义(P < 0.001)。
  • 作者认为结果提示外源性睾酮不引起子宫内膜增殖。

核心结论

  • 接受睾酮治疗的跨男性人群子宫内膜厚度显著低于未暴露睾酮的顺性别女性,作者认为这提示外源性睾酮不引起子宫内膜增殖。

研究设计与样本

  • 单中心、横断面队列研究,在阿姆斯特丹性别焦虑专业中心开展。
  • 2013至2015年纳入拟行性别肯定手术、已接受性别肯定激素治疗(睾酮)至少1年并提供知情同意的跨男性人群。
  • 跨男性人群在全麻下手术前即刻经阴道超声测量子宫内膜厚度,顺性别女性对照来自一般人群,在门诊环境中于月经周期第2-5天接受完全相同的经阴道超声测量。
  • 共纳入51例跨男性人群和77例对照。

主要发现

  • 睾酮使用平均时长30.2个月(SD 8.8)。
  • 跨男性人群子宫内膜中位厚度3.9 mm(IQR 2.8-5.1),顺性别女性为4.9 mm(IQR 4.0-6.3)。
  • 校正混杂因素(当前促性腺激素释放激素激动剂使用)后,跨男性人群子宫内膜厚度显著低于顺性别女性(P < 0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: What is the endometrial thickness of endometrium exposed to testosterone in transmasculine people compared with unexposed endometrium in cisgender women as determined by transvaginal ultrasound (TVU)? DESIGN: Single centre, cross-sectional cohort study conducted the Centre of Expertise on Gender Dysphoria in Amsterdam. Between 2013 and 2015, transmasculine people scheduled for gender affirming surgery (GAS) were included in this study after they provided informed consent. They were undergoing gender affirming hormone therapy (testosterone) for at least 1 year. Endometrial thickness (mm) was measured by TVU in transmasculine people, immediately before their GAS while under general anaesthesia. Cisgender control women from the general population underwent the exact same TVU measurements in an outpatient clinical setting on cycle days 2-5. RESULT: Fifty-one transmasculine people and 77 controls were included. The mean duration of testosterone use was 30.2 months (SD 8.8). Endometrial thickness was significantly lower in transmasculine people compared with cisgender women: median 3.9 mm (interquartile range [IQR] 2.8-5.1) and 4.9 mm (IQR 4.0-6.3), respectively (P < 0.001), after correcting for confounding factor (current gonadotrophin releasing hormone agonist use). CONCLUSIONS: Endometrial thickness in transmasculine people exposed to testosterone is significantly lower compared with cisgender women without testosterone exposure. These results suggest an absence of endometrial proliferation by exogenous testosterone.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Asseler JD, Caanen MR, Verhoeven MO, et al. Endometrial thickness assessed by transvaginal ultrasound in transmasculine people taking testosterone compared with cisgender women. Reprod Biomed Online. 2022. PMID: 35918245. doi:10.1016/j.rbmo.2022.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。